New dosing method could improve sickle cell treatment

NCT ID NCT07177300

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times

Summary

This study tests a new way to start hydroxyurea for people with sickle cell anemia. Instead of dosing based only on weight, the dose will be tailored to how each person absorbs the drug. The goal is to reduce organ damage and improve long-term health. About 50 participants with sickle cell anemia or sickle-β0-thalassemia will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA (HBSS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.